Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.857
+0.037 (2.02%)
Nov 11, 2025, 9:39 AM EST - Market open
Daré Bioscience Revenue
Daré Bioscience had revenue of $-21.17K in the quarter ending June 30, 2025, a decrease of -194.36%. This brings the company's revenue in the last twelve months to $-17.70K, down -100.62% year-over-year. In the year 2024, Daré Bioscience had annual revenue of $9.78K, down -99.65%.
Revenue (ttm)
$-17.70K
Revenue Growth
-100.62%
P/S Ratio
-1,355.10
Revenue / Employee
n/a
Employees
23
Market Cap
24.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DARE News
- 5 days ago - Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - GlobeNewsWire
- 6 weeks ago - Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewsWire
- 3 months ago - Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 - GlobeNewsWire
- 3 months ago - Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream - GlobeNewsWire
- 4 months ago - UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar - GlobeNewsWire
- 4 months ago - Crude Oil Moves Lower; Daré Bioscience Shares Jump - Benzinga